IRADIMED CORPORATION (NASDAQ:IRMD) Files An 8-K Entry into a Material Definitive AgreementItem 1.01 Entry Into a Material Definitive Agreement.
On July 17, 2017, Iradimed Corporation (the “Company”) and Roth Capital Partners, LLC (“Roth”) entered into an Amendment (the “Roth Amendment”) to the Warrant to Purchase Common Stock dated July 21, 2014 between the Company and Roth (the “Roth Warrant”). The Amendment extends the expiration date of the Roth Warrant to July 17, 2019 in exchange for an increase in its exercise price to $10.05.
On July 17, 2017, Iradimed Corporation (the “Company”) and Monarch Capital Group, LLC (“Monarch”) entered into an Amendment (the “Monarch Amendment”) to the Warrant to Purchase Common Stock dated July 21, 2014 between the Company and Monarch (the “Monarch Warrant”). The Amendment extends the expiration date of the Monarch Warrant to July 17, 2019 in exchange for an increase in its exercise price to $10.05.
On July 17, 2017, Iradimed Corporation (the “Company”) and Lisa Walters-Hoffert (“Walters-Hoffert”) entered into an Amendment (the “Walters-Hoffert Amendment” and, collectively with the Roth Amendment and the Monarch Amendment, the “Amendments”) to the Warrant to Purchase Common Stock dated July 21, 2014 between the Company and Roth, as partially assigned to Walters-Hoffert (the “Walters-Hoffert Warrant”). The Amendment extends the expiration date of the Walters-Hoffert Warrant to July 17, 2019 in exchange for an increase in its exercise price to $10.05.
The foregoing description of the Amendments is qualified in its entirety by reference to the full text of such documents, which are attached hereto as Exhibits 10.1 through 10.3.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
10.1 |
Roth Amendment |
|
10.2 |
Monarch Amendment |
|
10.3 |
Walters-Hoffert Amendment |
IRADIMED CORP ExhibitEX-10.1 2 ex10-1.htm AMENDMENT TO WARRANT TO PURCHASE COMMON STOCK This Amendment to Warrant to Purchase Common Stock (this “Amendment”),…To view the full exhibit click here
About IRADIMED CORPORATION (NASDAQ:IRMD)
IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, non-ferrous part and other features in order to deliver anesthesia and other IV fluids during various MRI procedures. MRI compatible IV infusion pump system includes the 3860+ MRI compatible IV infusion pump, single-use IV tubing sets, a non-magnetic pole and a lithium battery. In addition, it offers optional upgrade systems, including the 3865 Remote Display/Control, 3861 Side Car, Dose Error Reduction System (DERS) and SpO2 monitor.
